{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:34:06Z","timestamp":1792679646402,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canrad.2025.104770","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:33:13Z","timestamp":1763753593000},"page":"104770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of radiotherapy in the management of anal canal cancer: Recommendations of the Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0526-8632","authenticated-orcid":false,"given":"Charles","family":"Raynaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jolnerovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Schipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Moureau-Zabotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Bessi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-4616","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Vendrely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2025.104770_bib0185","first-page":"924","article-title":"International trends in anal cancer incidence rates","volume":"46","author":"Islami","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.canrad.2025.104770_bib0190","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.25671","article-title":"Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study","volume":"129","author":"Abramowitz","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.canrad.2025.104770_bib0195","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, Gercor, Unicancer, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.canrad.2025.104770_bib0200","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41416-019-0689-x","article-title":"Temporal improvements in locoregional failure and survival in patients with anal cancer treated with chemoradiotherapy: treatment cohort study (1990\u20132014)","volume":"122","author":"Sekhar","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2025.104770_bib0205","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2004.09.060","article-title":"Anal canal carcinoma: early-stage tumors\u00a0<\u00a0or\u00a0=\u00a010\u00a0mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy","volume":"62","author":"Ortholan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0210","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0215","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0220","doi-asserted-by":"crossref","first-page":"109542","DOI":"10.1016\/j.radonc.2023.109542","article-title":"Treatment, outcome, and prognostic factors in non-metastatic anal cancer: the French nationwide cohort study FFCD-Anabase","volume":"183","author":"Vendrely","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0225","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00a0\u00d7\u00a02 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0230","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ijrobp.2017.03.022","article-title":"Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer","volume":"98","author":"Goodman","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u00a0\u2013\u00a0a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0240","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1038\/bjc.2014.467","article-title":"Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option","volume":"111","author":"Meulendijks","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.canrad.2025.104770_bib0245","doi-asserted-by":"crossref","first-page":"665","DOI":"10.21037\/jgo.2016.06.04","article-title":"A comparison between 5-fluorouracil\/mitomycin and capecitabine\/mitomycin in combination with radiation for anal cancer","volume":"7","author":"Peixoto","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0250","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.3390\/curroncol30090621","article-title":"Capecitabine\/mitomycin versus 5-fluorouracil\/mitomycin in combination with simultaneous integrated boost intensity-modulated radiation therapy for anal cancer","volume":"30","author":"Mineur","year":"2023","journal-title":"Curr Oncol Tor Ont"},{"key":"10.1016\/j.canrad.2025.104770_bib0255","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized Unicancer Accord 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.canrad.2025.104770_bib0260","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.dld.2024.06.022","article-title":"Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: a comparative analysis of the French cohort FFCD-Anabase","volume":"57","author":"Buchalet","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.canrad.2025.104770_bib0265","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.dld.2021.03.015","article-title":"What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD Anabase cohort","volume":"53","author":"Bacci","year":"2021","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.canrad.2025.104770_bib0270","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.radonc.2021.12.050","article-title":"Evaluation of prognostic factors after primary chemoradiotherapy of anal cancer: a multicenter study of the German Cancer Consortium-Radiation Oncology Group (DKTK-ROG)","volume":"167","author":"Martin","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0275","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijrobp.2021.08.008","article-title":"Long-term outcomes of NRG Oncology\/RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-c for the reduction of acute morbidity in anal canal cancer","volume":"112","author":"Kachnic","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0280","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2004.09.060","article-title":"Anal canal carcinoma: early-stage tumors\u00a0\u2264\u00a010\u00a0mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy","volume":"62","author":"Ortholan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0285","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1245\/s10434-014-3849-5","article-title":"Chemoradiotherapy with a radiation boost for anal cancer decreases the risk for salvage abdominoperineal resection: analysis from the national cancer data base","volume":"21","author":"Geltzeiler","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0290","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2015.07.050","article-title":"Evaluation of a 36\u00a0Gy elective node irradiation dose in anal cancer","volume":"116","author":"L\u00e9pinoy","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0300","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0305","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0310","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.canrad.2013.02.006","article-title":"Curieth\u00e9rapie du canal anal","volume":"17","author":"Pommier","year":"2013","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2025.104770_bib0315","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/COC.0b013e31827e52a3","article-title":"Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity","volume":"37","author":"Mitchell","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0320","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13014-015-0477-6","article-title":"French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients","volume":"10","author":"Vendrely","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0325","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2025.104770_bib0330","first-page":"39","article-title":"Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal","volume":"6","author":"Chuong","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.canrad.2025.104770_bib0335","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5114\/jcb.2019.82804","article-title":"Long-term results of chemoradiation plus pulsed-dose-rate brachytherapy boost in anal canal carcinoma: a mono-institutional retrospective analysis","volume":"11","author":"Arcelli","year":"2019","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.canrad.2025.104770_bib0340","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.ijrobp.2012.09.034","article-title":"Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study)","volume":"85","author":"Moureau-Zabotto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2025.104770_bib0345","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.brachy.2013.09.006","article-title":"Dosimetric and clinical outcome in image-based high-dose-rate interstitial brachytherapy for anal cancer","volume":"13","author":"Kapoor","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.canrad.2025.104770_bib0350","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s13014-014-0240-4","article-title":"Interstitial high-dose rate brachytherapy as boost for anal canal cancer","volume":"9","author":"Falk","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0355","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.radonc.2022.03.019","article-title":"High dose rate brachytherapy in the management of anal cancer: a review","volume":"171","author":"Ali","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2025.104770_bib0360","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2967\/jnumed.124.267626","article-title":"Prognostic value of (18F)-FDG PET\/CT assessment after radiotherapy of squamous cell carcinoma of the anus in patients from the national multicentric cohort FFCD-Anabase","volume":"65","author":"Combet-Curt","year":"2024","journal-title":"J Nucl Med"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321825001866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:16:37Z","timestamp":1768738597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321825001866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1278321825001866"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104770","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of radiotherapy in the management of anal canal cancer: Recommendations of the Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2025.104770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104770"}}